Page 9 - TD-3-4

Tumor Discovery

EXPERT CONSENSUS
Expert consensus and current landscape of NUT

carcinoma: A comprehensive strategy from
diagnosis to treatment

3
Zhuomiao Ye 1,2† , Xin Li 1,2† , Fei Xie , Chao Deng , Dan Yang , Hongle Li 4 ,
3
1
5
6
7
9
8
Yuanzhi Lu , Zhenbin Mao , Qingwei Meng , Lidong Wang , Zhe Wang ,
11
Jinliang Xing 10 , Chong Bai , Zhimin Bian , Paolo Boffano , Steven Brower ,
14
13
12
15
16
Rui Chen , Wantao Chen , Jinhai Deng , Xinpei Deng , Chunming Ding ,
17
18
19
23
22
20
21
Jianchun Duan , Song Duan , Nejat Duzgunes , Pierfrancesco Franco ,
25
Guobin Fu , Longmei Guo , Ye Guo , Ruiqin Han , Ling Hao , Lang He ,
26
29
28
27
24
30
33
34
31
32
Yayi He , Xiaotong Hu , Junmei Jia , Yanfang Jiang , Weilin Jin ,
35
38
1
Kalevi Kairemo , Mohamed Kamal 36,37 , Evan T. Keller , Rensheng Lai ,
Abstract
Nuclear protein of the testis (NUT) carcinoma is a rare and highly aggressive malignancy
characterized by the rearrangement of the NUT midline carcinoma family member 1
† These authors contributed equally (NUTM1) gene. Nevertheless, standardized strategies for its diagnosis and treatment
to this work. remain unavailable, underscoring the need for expert consensus. To address this gap,
*Corresponding authors: we conducted a systematic review to gather comprehensive information on NUT
Mingzhu Yin carcinoma from five databases: PubMed, Web of Science, Embase, Cochrane Library,
(yinmingzhu@cqu.edu.cn);
Minghui Zhang and Ovid Medline. This expert consensus was collaboratively developed by a team
(zhmhui@cqu.edu.cn) of international multidisciplinary experts, in partnership with the NUT Carcinoma
Diagnosis Working Group of the Chinese Anti-Cancer Association’s Oncogene
Citation: Ye Z, Li X, Xie F, et al.
Expert consensus and current Diagnosis Professional Committee. This working group comprises medical oncologists,
landscape of NUT carcinoma: radiation oncologists, surgical oncologists, pathologists, nurses, molecular biologists,
A comprehensive strategy from statisticians, and bioinformatics specialists. A systematic review, based on data from
diagnosis to treatment. Tumor
Discov. 2024;3(4):4904. 526 patients across 199 articles, was conducted to comprehensively explore various
doi: 10.36922/td.4904 characteristics, including demographic features (e.g., patient gender, distribution
Received: September 22, 2024 regions, and age), tumor-node-metastasis (TNM) classification stage, clinical
symptoms, tumor size, metastatic patterns, immunohistochemical (IHC) findings,
Accepted: November 14, 2024
treatment modalities, prognosis-related information, and NUTM1 fusion partners.
Published Online: December 24, We have developed an expert consensus on diagnosing and treating NUT carcinoma
2024 using a multidisciplinary approach. The guideline provides eight recommendations,
Copyright: © 2024 Author(s). addressing epidemiological characteristics, clinical and imaging manifestations,
This is an Open-Access article pathological findings, IHC features, molecular mechanisms and subtypes, prognosis,
distributed under the terms of the
Creative Commons Attribution diagnosis, and treatment strategies for NUT carcinoma. Furthermore, an international
License, permitting distribution, platform has been established to disseminate NUT carcinoma knowledge and patient
and reproduction in any medium, recruitment, providing patients and healthcare providers access to NUT carcinoma-
provided the original work is
properly cited. related information and updates on clinical trial recruitment.
Publisher’s Note: AccScience
Publishing remains neutral with Keywords: Nuclear protein of the testis carcinoma; Expert consensus; Diagnosis;
regard to jurisdictional claims in
published maps and institutional Treatment
affiliations.
Volume 3 Issue 4 (2024) 1 doi: 10.36922/td.4904